Clinical utility of neurocognitive function (NCF), quality of life (QOL), and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525.

Terri S. Armstrong,Jeffrey Scott Wefel,Meihua Wang,Minhee Won,Andrew Bottomley,Tito R. Mendoza,Corneel Coens,Maria Werner-Wasik,D. Brachman,Ali K. Choucair,M. R. Gilbert

Clinical utility of neurocognitive function (NCF), quality of life (QOL), and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525.

2011

Terri S. Armstrong
Jeffrey Scott Wefel
Meihua Wang
Minhee Won
Andrew Bottomley
Tito R. Mendoza
Corneel Coens
Maria Werner-Wasik
D. Brachman
Ali K. Choucair
M. R. Gilbert

2016 Background: RTOG 0525, a randomized phase III study compared dose-dense (dd) versus standard dose (sd) temozolomide in patients with newly diagnosed glioblastoma. NCF tests, and Symptom and QO...

Keywords:

Physical medicine and rehabilitation
Physical therapy
Neurocognitive
Quality of life
Medicine
newly diagnosed
in patient
Glioblastoma
Temozolomide
symptom assessment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations